Drug intelligence / Profile preview

eseba-vec

Development stage: Unknown
Lead developer: HOOKIPA Pharma
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

Eseba-vec is an investigational **heterologous two-vector therapeutic cancer vaccine** developed from HOOKIPA's attenuated arenavirus-vector platform for HPV16-positive malignancies, principally recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma. The HB-200 regimen alternates two intravenously administered, replication-attenuated vectors: HB-201, derived from lymphocytic choriomeningitis virus, and HB-202, derived from Pichinde virus. Both express a non-oncogenic HPV16 E7E6 fusion antigen intended to generate potent HPV16 E6- and E7-specific CD8-positive T-cell responses against tumor cells. HOOKIPA completed Phase 2 development activities and sold the program to NeoTrail Therapeutics in March 2026. ([pro.ceo.ca](https://pro.ceo.ca/%40GlobeNewswire/hookipa-pharma-announces-completion-of-sale-of-oncology))

Other names: eseba-vec

Targets

HPV16 E6 oncoprotein

Beyond the preview

Go deeper on eseba-vec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eseba-vec.

Explore the full profile